Leaders across the health care continuum gathered yesterday in Washington, D.C., to discuss ways to improve payment and delivery systems in the private market and opportunities for producing and rewarding better value for patients.

During a meeting with President Donald Trump, Amgen CEO Robert Bradway told the president the company will be hiring 1,600 people across the United States in 2017.

Although virtually no one in the urban bubble where biopharmaceutical companies reside expected it to happen, Donald Trump won. So, now what?

The two leading biopharmaceutical organizations made a bold public statement on FDA off-label policy that proposes new regulatory standard that provides a great starting point for the inevitable policy debates on how the FDA defines “false and misleading” in marketing.

Four U.S. senators introduced a bill aimed at preventing big pharmaceutical companies from using safety rules to prevent generic drugs from coming to market.

The debate in Washington over drug pricing is getting louder and nastier, and drug marketing is getting caught in the crossfire.

The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of […]

U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters.   The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such […]

(Reuters) – Turing Pharmaceuticals, a small company that generated outrage over raising the cost of an old anti-infective drug by more than 5,000 percent, said on Tuesday it would roll back that increase to make sure it remains affordable. Turing Pharmaceuticals, a small company that generated outrage over raising the cost of an old anti-infective […]